Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundSwissMalen = 20 mice, 10 per group, further split by sacrifice dayTopical application to the wound0.1 mL of 30 mg/mL extract per applicationApplied on the days after surgery
Model: Full thickness excisional cutaneous wound, 1 cm diameter resection on the dorsum
No statistically significant macroscopic difference was seen at day 7 or day 14 (p = 0.120 and p = 0.186). The authors report better histological outcomes for healing, acute inflammation and fibrosis in the aveloz group at day 14, although the abstract describes the acute inflammation and fibrosis…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.